Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

The mechanosensitive ion channel Piezo2 is selectively expressed in enterochromaffin (EC) cells of the human and mouse gastrointestinal mucosa
Knutson, Kaitlyn R. , Wang, Fan , Alcaino, Constanza , Bernard, Cheryl E., Farrugia, Gianrico , Wang, Fan, Beyder, Arthur

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1254.5 Get It

BACKGROUND Enterochromaffin (EC) cells are enteroendocrine cells in the gastrointestinal (GI) epithelium that release serotonin (5‐HT) in response to a variety of stimuli including mechanical force. In turn, EC cell 5‐HT affects GI secretion, motility and sensation. The molecular mechanism of EC cell mechanotransduction is unknown. The recently discovered mechanosensitive ion channel Piezo2 is important in several mechanosensory cell types. AIM to determine if the mechanosensitive ion channel Piezo2 is expressed and functional in EC cells. METHODS Murine small bowel was collected, fixed in 4% paraformaldehyde, and frozen. Human and mouse RNA from human jejunum and mouse duodenum, jejunum and ileum was analyzed by quantitative RT‐PCR for Piezo2 mRNA. Piezo2 and 5‐HT were also identified by fluorescence immunolabeling. QGP‐1, a human enteroendocrine cell model, was analyzed by RT‐PCR for the presence of Piezo2 and immunolabeling was done to detect Piezo2 and 5‐HT. Piezo2 mechanically activated currents were recorded from QGP‐1 cells in whole‐cell configuration. Voltage‐clamped QGP‐1 cells were subjected to a series of mechanical perturbations using a piezo‐electrically driven glass probe at steps of 0.3 μm for stimulation. RESULTS Human jejunum and all segments of mouse small bowel mucosa (duodenum, jejunum, ileum) expressed Piezo2 mRNA. In human jejunum and all segments of mouse small bowel Piezo2 co‐localized with 5‐HT in >90% of 5‐HT containing cells. No Piezo2 immunoreactivity was seen outside of 5‐HT positive enterochromaffin cells. The enteroendocrine cell model QGP‐1 expressed both Piezo2 and 5‐HT by immunohistochemistry and RT‐PCR showed message for Piezo2. Application of force to the surface of voltage‐clamped QGP‐1 cells elicited whole cell fast inward non‐selective cation currents of ~200 pA (at −60 mV) that were blocked by Gd 3+ with kinetic properties compatible with Piezo2 channels. CONCLUSIONS Piezo2 is specifically expressed in human and murine small bowel EC cells and in the enteroendocrine cell model QGP‐1. QGP‐1 cells have a mechanosensitive inward cation current with kinetic and pharmacological properties similar to Piezo2. Our data suggest that Piezo2 is involved in EC cell mechanotransduction. Support or Funding Information Supported by NIH DK106456 , DK84567, DK052766
Characterization of Vitamin D and Serotonin Pathway Variations in Patients with Irritable Bowel Syndrome
Grozić, Aleksandra, Hockley, Maryam, Nickerson, Cheryl , Yale, Steven H. , Foxx–Orenstein, Amy E., Dussik, Christopher M. , Zhang, Lin , Park, Jin Kee , Wang, Jie , Sandrin, Todd R. , Jurutka, Peter W.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.828.2 Get It

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder associated with chronic abdominal pain along with recurrent diarrhea, constipation, or both that afflicts millions of people worldwide. Currently, the etiological foundation of the disorder remains enigmatic. However, there is mounting evidence suggesting that serotonin may play a critical role in the pathophysiology of IBS. DNA microarrays analyzing the transcriptomes of 11 IBS patients versus 13 asymptomatic control patients have identified a series of 858 differentially‐expressed genes that may characterize the IBS pathological state. Gene ontology (GO) analysis of this subset of genes revealed that nodes featuring serotonin‐related pathways displayed the highest number of functions relative to other GO groups. Quantitative real‐time polymerase chain reaction (qRT‐PCR) analysis of IBS patient‐derived RNA displayed reduced expression of the rate‐limiting enzyme of the serotonin biosynthetic pathway, tryptophan hydroxylase 1 (TPH1), relative to a pool of RNA comprised of eight control patients. Further, this analysis revealed potential compensatory regulation of several other genes integral to the maintenance of serotonin metabolism. In addition, concentrations of serum 25‐hydroxyvitamin D in both the IBS and control sampled populations indicated a trend towards decreased vitamin D levels within the IBS cohort, regardless of IBS subtype. Finally, vitamin D was shown to be effective in regulating the expression of several key serotonin metabolism genes, alluding to a potential link between vitamin D and serotonin pathways modulating IBS. These findings suggest that the pathogenesis of IBS may be associated with abnormal serotonin metabolism and/or vitamin D deficiency, and provide novel insight into possible treatment regimes. Support or Funding Information Wisconsin Network for Health Research
Induction of Fatty Acid Synthase is Required for Profibrotic TGFβ Signaling
Jung, M. Katherine , Hernandez, Danielle, Lupu, Ruth , Leof, Edward B. , Jung, Mi‐Yeon, Kang, Jeong Han , Wang, Youli , Hernandez, Danielle

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1119.3 Get It

Alterations in cellular metabolism are known to play critical roles in a variety of normal as well as pathological processes, including (but not limited to) cancer, hepatic steatosis, and cell differentiation. While TGFβ is routinely considered a pleotropic cytokine due to its ability to impact numerous diseases and biological phenotypes, the role of metabolism in profibrotic TGFβ signaling is relatively unexplored/unknown. Fatty Acid Synthase (FASN) is the primary anabolic enzyme responsible for the de novo synthesis of fatty acids. Renewed interest in FASN has been sparked by the recognition of the critical inter‐relation of metabolic dysregulation and tumor progression with the findings that (i) FASN levels are significantly increased in numerous human tumors including breast, prostate, colorectal, and ovarian; and (ii) the efficacy of ErbB receptor inhibitors is enhanced by inhibiting FASN activity. In the current study we show that FASN expression is regulated by TGFβ in multiple murine and human fibroblasts, required for profibrotic TGFβ signaling, and, most importantly, treatment with C75 ((trans‐4‐carboxy‐5‐octyl‐3‐methylenebutyrolactone, a novel cerulenin‐derived semi‐synthetic FASN inhibitor) abrogates pathologic and physiologic changes in a murine model of lung fibrosis. Support or Funding Information This work was supported by Public Health Service grants GM‐055816 and GM‐054200 from National Institutes of General Medical Sciences.
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients—A Tale of Two Cities
Mannan, Rahul , Zhang, Yuping , Chinnaiyan, Anya, Rangaswamy, Roshni, Chugh, Seema , Cao, Xuhong , Hafez, Khaled S., Vaishampayan, Ulka N. , McKenney, Jesse K. , Gupta, Sounak , Tretiakova, Maria , Argani, Pedram , Mehra, Rohit , Vaishampayan, Ulka , Tretiakova, Maria S , Wang, Xiaoming , Su, Fengyun , Wang, Rui , Skala, Stephanie L. , Picken, Maria M. , Alaghehbandan, Reza , Chinnaiyan, Arul , Dhanasekaran, Saravana Mohan

Mayo Clinic

American Journal of Surgical Pathology | November 23, 2023 | Volume: 48 | Issue: 2 | Pages: 163-173

10.1097/pas.0000000000002152 | PMID 37994665 Get It

Birt-Hogg-Dubé (BHD) syndrome is associated with an increased risk of multifocal renal tumors, including hybrid oncocytic tumor (HOT) and chromophobe renal cell carcinoma (chRCC). HOT exhibits heterogenous histologic features overlapping with chRCC and benign renal oncocytoma, posing challenges in diagnosis of HOT and renal tumor entities resembling HOT. In this study, we performed integrative analysis of bulk and single-cell RNA sequencing data from renal tumors and normal kidney tissues, and nominated candidate biomarkers of HOT, L1CAM, and LINC01187, which are also lineage-specific markers labeling the principal cell and intercalated cell lineages of the distal nephron, respectively. Our findings indicate the principal cell lineage marker L1CAM and intercalated cell lineage marker LINC01187 to be expressed mutually exclusively in a unique checkered pattern in BHD-associated HOTs, and these 2 lineage markers collectively capture the 2 distinct tumor epithelial populations seen to co-exist morphologically in HOTs. We further confirmed that the unique checkered expression pattern of L1CAM and LINC01187 distinguished HOT from chRCC, renal oncocytoma, and other major and rare renal cell carcinoma subtypes. We also characterized the histopathologic features and immunophenotypic features of oncocytosis in the background kidney of patients with BHD, as well as the intertumor and intratumor heterogeneity seen within HOT. We suggest that L1CAM and LINC01187 can serve as stand-alone diagnostic markers or as a panel for the diagnosis of HOT. These lineage markers will inform future studies on the evolution and interaction between the 2 transcriptionally distinct tumor epithelial populations in such tumors.
One-year clinical outcomes and the impact of procedural configurations in patients with left atrial appendage occlusion
Gao, Chao , Liu, J Z , Zhang, T T , Liu, Haoxian , Soliman, Osama , Holmes, David R. , Tao, Ling , Su, F, Wang, P, Garg, Scot , Serruys, Patrick W.

Mayo Clinic

European Heart Journal | November 22, 2023 | Volume: 44 | Issue: Supplement_2 | Pages: No page available

10.1093/eurheartj/ehad655.2091 Get It

Abstract Background To evaluate the long-term clinical performance, the impact of procedural configurations and post-procedure medications in atrial fibrillation patients with percutaneous left atrial appendage occlusion (LAAO). Methods The RECORD study was a prospective, all-comers registry conducted in 39 Chinese centers that consecutively enrolling patients who received LAAO between 1st April 2019 and 31st October 2020 with minimum inclusion and exclusion criteria. Events including any death, any stroke, systemic embolism and bleeding event were collected at 1 year and adjudicated by an independent clinical event committee. Cox proportional hazard models with multivariable adjustments were applied to estimate hazard ratios (HRs) for each outcome. Results Of the 3,096 participants, 3,082 successfully received an LAAO implant and 3,013 (97.8%) completed the 1-year follow-up. Participants had a high risk of stroke (mean CHA2DS2-VASc score of 4.0) and a moderate-to-high risk of bleeding (mean HAS-BLED score of 2.4). Local anesthetic was performed in 1,287 (41.6%) patients and fluoroscopy guidance in 492 (16.0%) patients. In 1295 (42.0%) cases, one-stage combination procedures of LAAO and radiofrequency ablation or cryoablation (CA) were performed. At 1 year, the composite ischemic endpoint of death, stroke, and systemic embolism occurred in 133 (4.51%) patients. Any life-threatening, disabling or major bleeding events occurred in 71 (2.36%) patients. There was no significant association between the type of anesthesia (general versus local), modality of image guidance (TEE, ICE, or fluoroscopy) with the ischemic or bleeding events. Combination procedures of LAAO plus CA was associated with a significantly lower rate of death, stroke, or systemic embolism than performing LAAO only (3.5% versus 5.2%, HRadjusted:0.69, 95%CI:0.48-0.98, P=0.041). The commonest antithrombotic strategy was OAC | APT | APT (38.1%; corresponded to medication prescribed at discharge | 45 days | 6 months), followed by OAC | OAC | APT (27.0%). Compared with OAC | APT | APT, the OAC | OAC | APT group was associated with a higher risk of life-threatening, disabling or major bleeding (1.2% versus 2.5%, HRadjusted:0.50, 95%CI: 0.25-0.99, P=0.47); whereas the risk of death, stroke and SE was numerically similar (2.9% versus 3.0%, HRadjusted:1.05, 95%CI: 0.61-1.78, P=0.867). There was no significant difference between OAC | APT | APT and OAC+APT | APT | APT groups regarding ischemic events; however, in patients with HAS-BLED ≥ 3, OAC | APT | APT was associated with lower rates of life-threatening, disabling or major bleeding events (1.1% versus 4.8%, HRadjusted:4.55, 95%CI: 1.31-15.81, P=0.017). Conclusion In Chinese centers, patients with a WATCHMAN LAAO device had low rates of ischemic and bleeding events at 1 year. One-stage combination procedures of LAAO and catheter ablation was associated with a significantly lower rate of ischemic events than performing LAAO only.Procedural configurations to outcomesPost-LAAO antithrombotic medications
Incarceration and screen-detectable cancer diagnosis among adults in Connecticut
Richman, Ilana B. , Soulos, Pamela R. , Lin, Hsiu‐Ju , Aminawung, Jenerius A. , Oladeru, Oluwadamiloa T, Puglisi, Lisa B. , Wang, Emily A. , Gross, Cary P.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 22, 2023 | Volume: 116 | Issue: 3 | Pages: 485-489

10.1093/jnci/djad242 | PMID 37991935 Get It

Abstract Although incarcerated adults are at elevated risk of dying from cancer, little is known about cancer screening in carceral settings. This study compared stage-specific incidence of screen-detectable cancers among incarcerated and recently released people with the general population, as a reflection of screening practices. We calculated the age- and sex-standardized incidence ratios (SIR) for early- and late-stage cancers for incarcerated and recently released adults compared to the general Connecticut population between 2005 and 2016. Our sample included 143 cancer cases among those incarcerated, 406 among those recently released, and 201 360 in the general population. The SIR for early-stage screen-detectable cancers was lower among incarcerated (SIR = 0.28, 95% CI = 0.17 to 0.43) and recently released (SIR = 0.69, 95% CI = 0.51 to 0.88) individuals than the general population. Incidence of late-stage screen-detectable cancer was lower during incarceration (SIR = 0.51, 95% CI = 0.27 to 0.88) but not after release (SIR = 1.32, 95% CI = 0.93 to 1.82). Findings suggest that underscreening and underdetection of cancer may occur in carceral settings.
Closing the gender gap in the authorship of hematology/oncology-related randomized controlled trials requires inclusive effort from male and female senior researchers
Kumari, Roopa, Khealani, Milan, Luhana, Sindhu, Parkash, Om , Sadarat, FNU, Kiran, FNU, Rahaman, Zubair, Wang, Hong Yu , Parkash, Om, Devi, Sapna, Chander, Subhash

Mayo Clinic

No container title available | November 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3628199/v1 Get It

Abstract Importance: Severe gender gap in academic research output is pervasive across all medical specialties, including hematology and oncology. Objective: This bibliometric study aimed to investigate the representation of females in premier first and last authorship positions of hematology- and oncology-related randomized controlled trials (RCTs) published between 2000–2022. Additionally, we investigated the trend of females in first authorship positions with a male or female senior author. Design: Bibliometric analysis of clinically oriented hematology and oncology RCTs published between 2000 and 2022 across all PubMed-indexed journals. Participants: First and last authors of 5,891 hematology- and oncology-related RCTs. Main Outcomes: Change in the proportion of female first and senior authors and the proportion of RCTs with the same and cross-gender dyads of first and senior authors. Results: 5,891 RCTs were available with identifiable gender of first and senior authors. A total of 49 countries and 62 journals were represented in our study sample. The proportion of females in our study population was 22.9% (n = 1,349) in the first authorship and 17.5% (n = 1,032) in the senior authorship positions and were predominantly affiliated with institutions in high-income countries (94.1%, n = 1,270 and 95.3%, n = 984). We also noted a significant upward trend in the percentage of female authors in the first authorship position (16.3% in 2000 to 32.4% in 2022, p = 0.001) between 2000 and 2022; the trend was stronger with male than female senior authors. However, the odds of the females in the first authorship position with a female senior author were significantly higher only when both authors came from high-income countries [OR = 1.702 (95%CI 1.461–1.984; p < 0.0001]. The proportion of female senior authors remained stable during the study period. Conclusions and Relevance: Despite early trends in closing the gender gap in the authorship of hematology- and oncology-related RCTs, females remain severely underrepresented in premier authorship positions. The increasing proportion of female authors in the first authorship position with a male senior author indicated that a more inclusive effort to train, mentor, and encourage young female physician-scientists with the involvement of senior male and female researchers will likely accelerate the overall increase in female authorship.
Patients With Esophageal Adenocarcinoma With Prior Gastroesophageal Reflux Disease Symptoms Are Similar to Those Without Gastroesophageal Reflux Disease: A Cross-Sectional Study
Chandar, Apoorva K., Keerthy, Komal S. , Gupta, Rajesh , Grady, William M. , Canto, Marcia Irene , Shaheen, Nicholas J. , Thota, Prashanthi N. , Iyer, Prasad G. , Wang, Jean S. , Falk, Gary W. , Dumot, John A. , Markowitz, Sanford D. , Willis, Joseph , Moinova, Helen , Guda, Kishore , Brock, Wendy , Chak, Amitabh , Keerthy, Komal , Abrams, Julian A , Dumot, John , Brock, Wendy , Chak, Amitabh , Willis, Joseph E , Grady, William M , Faulx, Michael

Mayo Clinic

American Journal of Gastroenterology | November 17, 2023 | Volume: 119 | Issue: 5 | Pages: 823-829

10.14309/ajg.0000000000002593 | PMID 37975600 Get It

INTRODUCTION: A substantial proportion of patients with esophageal adenocarcinoma (EAC) do not report gastroesophageal reflux disease (GERD) symptoms. This study aimed to compare the risk factor profiles and cancer stage at presentation of patients with EAC with and without prior GERD. METHODS: In this retrospective cross-sectional study, patients with EAC were divided into 2 cohorts: (i) EAC with prior GERD: patients who reported typical GERD symptoms (heartburn or regurgitation) ≥1 year before cancer diagnosis and (ii) EAC without prior GERD: patients who did not report prior GERD symptoms or reported symptoms within 1 year of their cancer diagnosis. Baseline demographics, risk factors, and cancer stage at presentation were compared between the 2 cohorts. In addition, the distribution of patients based on numbers of BE/EAC–associated risk factors (1, 2, 3, 4, and 5 or more) was examined in the symptomatic and asymptomatic cohorts. RESULTS: Over 13 years, 388 patients with EAC with prior GERD and 245 patients with EAC without prior GERD were recruited. Both groups had similar baseline demographics and risk factors, but patients with EAC with prior GERD were more likely to have a history of BE. Asymptomatic patients had more advanced disease. Patients with 3 or more BE/EAC–related risk factors formed the largest proportion of patients in both the symptomatic and asymptomatic cohorts. DISCUSSION: Patients with EAC with and without prior GERD symptoms are phenotypically similar, suggesting that BE screening efforts to prevent or detect early EAC should not be restricted to just those with GERD.
CTNI-01. LONG-TERM RESULTS FROM A PHASE 1 TRIAL OF SPINE SBRT IN INOPERABLE PATIENTS WITH CORD COMPRESSION
Ghia, Amol J. , McAleer, Mary Frances , Briere, Tina M. , Brown, Paul D. , Wang, Chenyang , Chang, Eric , Rhines, Laurence D. , Guha‐Thakurta, Nandita , Li, Jing , Tatsui, Claudio Esteves , Beckham, Thomas Hendrix , Yeboa, D.N.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v72-v73

10.1093/neuonc/noad179.0283 Get It

Abstract PURPOSE/OBJECTIVE We seek to establish the feasibility of using spine stereotactic radiosurgery (SSRS) allowing for spinal cord dose constraint relaxation as the primary management of metastatic epidural spinal cord compression (MESCC) in inoperable patients monitoring for radiation myelopathy (RM) and radiographic local control (LC). MATERIAL/METHODS Patients with radiation naïve MESCC were enrolled on this prospective Phase 1 trial. Single fraction SSRS was delivered to a dose of 18 or 24 Gy. Spinal cord constraint relaxation was performed in sequential cohorts from an initial allowable Dmax cohort of 10 Gy up to 16 Gy only if tumor progression occurred without RM. RESULTS Thirty two patients enrolled on the trial of which 4, 12, 8 and 8 were in the 10 Gy, 12 Gy, 14 Gy and 16 Gy cord Dmax cohorts, respectively. At baseline, there were 10 sites with MESCC Grade 1B, 10 sites with Grade 1C, 9 sites with Grade 2, 2 sites with Grade 1A, and 1 site with Grade 3 disease. Of the 28 evaluable patients, the median overall survival was 32.3 months (range 5.8-122.6 mo). The 1-year and 5-year LC was 84.5% and 79.5%. The 2-year LC did not statistically differ between the 14-16 Gy cord Dmax combined cohorts and the 10-12 Gy cord Dmax combined cohorts (92.9% vs. 62.9%, p = 0.15). With a median clinical follow-up of 22.7 months (range 3-122.3 mo), there were no cases of RM including in the 13 patients who survived at least 3 years. In the cohort receiving a cord Dmax of 16 Gy, there were no cases of RM with a median follow-up of 18.6 mo (range 9.0-97.1 mo). CONCLUSION With long-term follow-up, these data demonstrate that SSRS is a safe and effective tool in patients with MESCC. Cord constraint relaxation may be considered in inoperable patients with MESCC.
EXTH-77. EXTENDED HALF-LIFE IL-2 SYNERGIZES WITH Α-PD-1 FOR TREATMENT OF PRECLINICAL MURINE GLIOBLASTOMA MODELS
Tritz, Zachariah P. , Wolf, Delaney, Johnson, Aaron J. , Campian, Jian , Malo, Courtney S. , Yokanovich, Lila T. , Wang, Chensu , Vile, Richard G. , Mercano, Rosa, Wittrup, Dane, Maynes, Mark , Owens, Carley A. , Ayasoufi, Katayoun , Wolf, Delaney M. , Parney, Ian F. , Hanson, Michael, Jin, Fang , Johnson, Aaron J. , Fain, Cori E. , Himes, Benjamin , Goddery, Emma N. , Moynihan, Kelly D , Irvine, Darrell J , Maynes, Mark A

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v242-v242

10.1093/neuonc/noad179.0930 Get It

Abstract α-PD-1 checkpoint blockade is a promising immunotherapeutic approach for many solid tumors; however, this strategy is minimally effective for GBM patients as a monotherapy. One potential reason why α-PD-1 checkpoint blockade is ineffective is the tumor microenvironment and systemic derangements of the immune system which are prevalent in GBM patients. We have successfully modeled peripheral immune derangements in experimental murine GBM models. These include low peripheral blood CD4 T cell counts, reduced MHC class II expression on monocytes, and atrophy of primary immune organs in animals harboring gliomas. We therefore hypothesized that extended half-life IL-2, a potent cytokine which promotes the proliferation, differentiation, and killing activity of T cells, could overcome immune derangements and could potentially synergize with α-PD-1 checkpoint blockade therapy. In cohorts of C57Bl/6 mice, we supplemented α-PD-1 checkpoint blockade with multiple bio-engineered extended half-life IL-2 molecules to treat GL261 and CT2A orthotopic glioma models which are normally resistant to monotherapy. We observe a statistically significant increase in survival in GL261-bearing animals receiving the combination of extended half-life IL-2 reagents and αPD-1 therapy relative to control-treated mice. Some animals receiving this combination therapy had a reduction in tumor burden to levels below detection. These long-term survivors underwent a rechallenge experiment with a second inoculation of GL261-Luc and effectively cleared tumor without further therapeutic intervention. This intervention causes a significant shift in the immune profile, including the formation of mature T cell responses, as well as restoring the diminished peripheral immune cell counts in GL261-bearing animals. Finally, combining extended half-life IL-2 with α-PD-1 checkpoint blockade is effective independently of the CD8 T cell response. Together, these data suggest that combination immunotherapies employing extended half-life IL-2 fusion proteins are translational to the clinic and do not require the identification of tumor specific antigens for efficacy